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Background: Nutritional deficiencies are widespread in people living with HIV (PLWH), prior 
to the antiretroviral treatment (ART). Nutrient deficiencies and other nutrition-related conditions, 
however, have been identified in patients receiving ART. Trials of nutritional supplementation 
have been conducted to alleviate these nutritional conditions and improve or reverse nutrition-
related outcomes. This review aims to evaluate the benefits of supplementation, its unintended 
adverse effects, and the difference in approach and focus, research design, formulations, and 
outcomes between those randomized clinical trials (RCTs) conducted before and after the 
initiation of ART.
Methods: An evidence-based systematic review of the literature was conducted using electronic 
databases and the resources of the Florida International University Research Library. Forty-two 
RCTs were selected for review, and their design and outcomes were compared and contrasted 
conceptually and in the form of tables.
Results: Most of the RCTs (n=31) were conducted before the advent of ART, and their aims 
were delaying disease progression, reversing malnutrition, and improving pregnancy outcomes 
in women and infants infected with HIV. The RCTs conducted with coadministration of ART 
were fewer (n=11), with relative smaller sample size, of shorter duration, and mainly focused on 
preventing or ameliorating the nutrition-related conditions generated by the chronic infection, 
its treatment, and the aging of PLWH.
Conclusion: As ART is becoming more accessible worldwide, and people are living longer 
with the disease, more longitudinal trials of nutritional interventions with larger sample sizes 
are needed to study the nutritional consequences and potential treatments for PLWH.
Keywords: HIV, antiretroviral therapy, micronutrients, probiotics, AIDS, randomization, 
clinical trial
Introduction
In limited-resource countries, severe malnutrition continues to be a growing problem, 
and it is frequently superimposed on the ongoing HIV pandemic.1 Studies among people 
living with HIV (PLWH) have found metabolic and nutritional abnormalities, which 
may be either secondary to the HIV infection or due to primary malnutrition caused 
by insufficient intake. Nutritional deficiencies, when present, compromise the immune 
system and facilitate HIV disease progression.2 In HIV disease, immunodeficiency and 
deficits in nutrition interact early in the disease, before antiretroviral treatment (ART) 
is provided; however, nutritional deficits and its possible consequences have also been 
observed after the disease is managed with ART.3,4 Antiretrovirals are life-saving medi-
cations that, although do not cure the disease, control its progression5,6 and improve 
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nutritional status7,8 but generate new nutritional challenges. 
The nutritional problems observed in patients on ART dif-
fer from those seen prior to the provision of treatment;7,9–11 
therefore, the purpose and formulation of the nutritional 
supplementation should also change. Different from previous 
reviews of nutritional supplementation in HIV infection, this 
review of randomized clinical trials (RCTs) of nutritional 
supplementation in PLWH for the first time considers the 
coadministration of ART and divides the review according 
to whether antiretrovirals were used in the trials.
ART suppresses the HIV virus and helps in the recupera-
tion of the immune function. However, only about one-third 
of patients who achieve viral control recover protective 
immunity. Poor recovery of the immune function places 
these patients at increased risk of morbidity and mortality.12–14 
Moreover, ART combinations containing some of the early 
antiretrovirals may increase oxidative stress, mitochondrial 
injury, and increase the host’s needs for antioxidants.15–20 
Chronic ART has also been associated with gastrointestinal 
(GI) symptoms that may decrease nutrient absorption and 
metabolism.21
Several reports suggest that micronutrient supplemen-
tation may support the immune system before and during 
the chronic use of ART22–25 and prevent ART-associated 
mitochondrial damage.26,27 Multivitamins and minerals 
are essential for supporting innate immunity, preventing 
its decline and promoting a timely reconstitution of the 
specific immune system.15–18,23,28 Most of the RCTs of 
nutritional supplementation reviewed by this work were 
performed before the availability of ART and demonstrated 
the immunostimulatory effects of micronutrients in PLWH 
(Table 1).
The trials in which nutritional supplements were coad-
ministered with ART are few (Tables 2 and 3), with a limited 
sample size and duration of supplementation. The lack of 
emphasis on nutritional supplementation after the advent 
of ART might be due to expectations that treatment with 
antiretrovirals would have reversed nutritional and metabolic 
alterations. The interpretation of the findings of RCTs in 
which nutritional supplements were coadministered with 
ART is complex. ART combinations are multiple, and the 
selection of the combination for a given patient depends on 
the genetics of the host and virus, the degree of resistance 
to certain antiretrovirals, and personal and national socio-
economic conditions.
This review highlights the benefits of nutritional supple-
mentation before ART is initiated and the scarcity of suffi-
ciently powered RCTs that evaluate the impact of nutritional 
supplementation during ART on immune recovery, morbidity, 
and mortality in PLWH.
Background
The literature indicates that nutritional deficiencies are 
widespread in PLWH, which are manifested early in the 
infection, before clinical symptoms are present, and prior 
to initiating ART.28–38 Although the use of ART has been 
shown to reduce wasting, the condition is still prevalent 
among patients receiving ART.10 In the era of ART, wasting 
is more frequently observed in cases with virologic and/or 
immunological failure, who are living in poor socioeconomic 
conditions and with high food insecurity.10,39 Micronutrient 
deficiencies have also been observed, even in patients receiv-
ing chronic ART. Jones et al40 reported a high prevalence of 
zinc deficiency in participants on ART, adjusting for param-
eters of acute-phase reaction.
The continuous struggle of the immune system to control 
HIV may produce a hypermetabolic state, which is associated 
with increased caloric expenses, high rates of fat oxidation,41 
and rapid depletion of essential micronutrients.29 Therefore, 
adequate nutritional intake is critical for PLWH, particularly 
before initiation of ART, to offset the increased nutritional 
needs for calories and proteins produced by competition for 
these nutrients with the virus and the demands placed by a 
continuously activated immune system. The development 
of combined ART brought expectations that, once the virus 
was under control, the immune system would recover, the 
increased nutritional demands would diminish, and nutri-
tional disturbances would be reversed.
Depletion of memory T-cells in the GI mucosa is the 
consequence of symptoms of diarrhea and malnutrition 
caused by HIV, which in turn causes bacterial translocation, 
which furthers immune activation, inflammation and oxida-
tive stress, contributing to HIV progression.42–44 Other GI 
manifestations observed in the pre-ART era were chronic 
enteropathy and altered GI integrity.45,46
ART, however, has also affected GI integrity; patients 
receiving ART have complications related to colitis associ-
ated with antimicrobial medications, side effects of ART,47 
and changes in microbiota.48 Bacterial translocation pro-
duced by altered gut integrity has been linked with failure 
of immune recovery after initiation of ART.49 Therefore, 
as it has been concluded for other conditions, it is impor-
tant to consider strategies to improve GI integrity and 
reduce bacterial translocation by improving the composi-
tion of the microbiota through the optimization of probiotic 
supplementation.50–52
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Nutritional interventions need to be individualized to 
the signs and conditions manifested by the patient, before 
or coadministered with ART, to preserve the innate immune 
response, support the recuperation of the immune system, 
and prevent comorbidities.25
Micronutrient deficiencies associated with untreated 
HIV infection are vitamins A, C, E and D, B vitamins, and 
antioxidant minerals: selenium and zinc.29,33,34,53–55 Although 
a Cochrane review56 found no definite evidence of the role 
of nutritional supplementation on morbidity, mortality, 
and HIV disease progression among PLWH, and vitamin 
A supplementation seems to be beneficial only in chil-
dren, subsequent reports from RCTs of supplementation 
have found benefits for both adults and children.23–25,39,57–72 
ART and nutritional supplementation are not in contradic-
tion, as concluded by another review,73 as each of them 
support the recovery of the immune system by different 
mechanisms.
This review focuses on evaluating RCTs of supplemen-
tation and their outcomes. Most of the RCTs reviewed had 
limitations, due to differences in length of supplementation, 
lack of measures of plasma levels of the supplemented micro-
nutrients at baseline, diversity of the nutrients included in the 
formulas, and the variety in doses.
A number of RCTs reviewed also reported adverse 
unintentional outcomes of supplementation, such as the 
association of vitamin A supplementation with increased 
mother-to-child transmission,25 iron with increased mor-
tality,74 selenium with vaginal HIV-shedding,68 zinc with 
wasting in pregnant women receiving 25 mg of zinc,75 
and zinc in a dose of 100 mg elemental zinc/d with 
more frequency of diarrhea in patients with diarrheal 
condition.76
Reports from RCTs that supplemented multivitamins 
with minerals demonstrated better outcomes than supple-
mentation with a single nutrient.77 Supplementation with 
multiple nutrients compared to a single nutrient on HIV 
disease outcomes suggests a synergistic interaction among 
nutrients (Tables 1 and 2), especially with nutritional 
antioxidants with a high level of metabolic interactions.73 
Because the efficacy of nutritional supplementation on 
HIV-disease parameters changes with the use of ART, the 
trials of supplementation were divided into two categories: 
trials in ART-naïve populations (Tables 1 and 3) and trials 
in which supplementation was coadministered with ART 
(Tables 2 and 3).
Some of the RCT formulas from the reviewed articles 
contained nonnutritional substances that were not directly 
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addressed in this review and which are listed as nonnutrients 
in Tables 1 and 2. The observational research on these 
nonnutrient substances is scarce, and their evaluation is 
beyond the focus of this review.
Methods
This review followed the five steps of the Academy of 
Dietetics and Nutrition for conducting evidence-based 
review.78 A systematic search of literature was conducted 
using PubMed and the resources of the Florida International 
University Library, including the Expanded Academic 
ASAP, Academic OneFile, Student Resources in Context, 
and Academic Search Complete to identify high-quality 
primary reports from RCTs of micronutrient and probiotic 
supplementation (Figure 1). The RCT design is considered 
to provide the strongest evidence.78 The inclusion criteria 
for articles reviewed here were primary reports of RCTs 
in HIV-seropositive patients, $30 participants, published 
in the last 15 years, in English, and with and without coad-
ministration of ART. Articles that did not meet the inclusion 
criteria were excluded after examination. The keywords 
used were HIV, nutrition, supplementation, RCT, micronu-
trients, vitamin, mineral, probiotic, and microbiota in dif-
ferent combinations to foster a wide number of results. The 
final selection included 42 reports of RCTs of nutritional 
supplementation in PLWH. These were divided into two 
categories: those conducted prior to the initiation of ART 
(n=31) and those in which nutritional supplementation was 
coadministered with ART (n=11).
The research questions that guided the review were
•	 Is nutritional supplementation beneficial in PLWH before 
and after the initiation of ART?
•	 How the objectives of the intervention differ before and 
after receiving ART?
Results
The majority of the formulas described in the reviewed 
reports (Tables 1–3) included several levels of B 
vitamins (thiamin, riboflavin, niacin, B
6
, B
12
, and 
folate)23,25,57–66,68–72,79–87 as these are important in the energy 
cycle of the mitochondria and for prevention of mito-
chondrial oxidative stress. Other antioxidant nutrients 
such as vitamins A, C, and E, selenium, and zinc were 
also included because the immune response to a chronic 
infection and some ART combinations may aggravate 
mitochondrial and systematic oxidative stress.15–19 Calcium 
and vitamin D were included in the formulas provided to 
cohorts that were coadministered ART23,88–90 because some 
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of the treatment combinations, and HIV itself, seem to 
expose PLWH to bone mass losses.91–96 These nutrients 
were supplemented either at the Recommended Dietary 
Allowance (RDA) levels97 or at several times the RDA 
values. Summarizing the conclusions is difficult because 
of the various supplements provided in each trial and the 
lack of dose–response studies, but most outcomes of the 
studies that included these micronutrients showed that 
they were effective in delaying HIV disease progres-
sion and safe in ART-naïve populations (Table 1) and 
after ART initiation when given at nutritional doses (one 
RDA or under Tolerable Upper Intake Levels) (Table 2). 
Table 3 describes the trials that included probiotics in 
their formula.
RCTs of micronutrients in ART-naïve 
PLwH
Of the 29 RCTs reviewed in Table 1, 15 reports are from a 
longitudinal RCT of supplementation conducted in Tanzania, 
which included 1,078 HIV-infected, ART-naive pregnant 
women who were followed for a median of 71 months. 
These pregnant women received 30 mg β-carotene + 5,000 
IU preformed vitamin A alone, or a multivitamin with 
B vitamins and vitamins C and E alone, or a combina-
tion of both, or placebo in a 2×2 factorial design. In this 
trial, their newborns were followed for 18–24 months and 
supplemented with standard 100,000 IU of vitamin A at 
6 months and 200,000 IU at 1 year of age and every 6 months 
thereafter.25,61–65,69–72,80,81,84,85
Table 3 Randomized clinical trials of probiotic supplementation
Authors (year) Population Design Formula Outcomes
In PLWH (pre-ART)
Hummelen et al 
(2011)103
112 ART-naïve Hiv 
patients in Tanzania
Randomized, double-
blind, controlled trial of 
micronutrient and yogurt 
for 4 weeks
Micronutrient fortified yogurt with/
without additional probiotic. Amount pert 
125 g of yogurt: Lactobacillus rhamnosus 
GR-1 at 109 CFU/mL; vit A at 1,500 iU; vit e 
at 5.7 iU; niacinamide at 3.8 mg; thiamin at 
0.3 mg; vit B12 at 0.6 μg; vit B6 at 0.3 mg; 
vit C at 21 mg; iron at 3.3 mg; selenium at 
13.8 μg; zinc at 2.4 mg; DHA (omega-3) at 
13 mg, and ePA (omega-3) at 19 mg
Micronutrient fortified 
yogurt was well 
tolerated by PLwH but 
not associated with a 
further increase in CD4 
count after 4 weeks of 
supplement
Hummelen et al 
(2010)104
65 Hiv+ women with 
aberrant microbiota in 
Tanzania (Nugent score 
4–10)
Randomized, double-blind, 
placebo-controlled trial 
for 6 months
L. rhamnosus GR-1 and Lactobacillus reuteri 
RC-14 supplementation compared to 
placebo
Supplementation of 
probiotic L. rhamnosus 
GR-1 and L. reuteri 
RC-14 did not enhance 
the cure of bacterial 
vaginitis but significantly 
increased beneficial pH 
(OR =3.8, P=0.02)
In HIV population (post-ART)
van Niekerk et al 
(2014)105
74 Hiv-exposed and 110 
nonexposed premature 
(,34-week gestation) 
infants with a birth 
weight of $500 g and 
#1,250 g in Cape Town, 
South Africa
Randomized, double-blind, 
placebo-controlled trial 
supplemented for 28 days
Study group: breast milk plus a daily 
probiotic supplement of L. rhamnosus GG 
(0.35×109 colony-forming units [CFU]) and 
Bifidobacterium infantis (0.35×109 CFU); 
control group: breast milk plus a placebo 
consisting of medium-chain triacylglycerol 
(MCT) oil
Probiotics did not affect 
growth outcomes or 
incidence of feeding 
intolerance in Hiv-
exposure infants, but 
they had significantly 
higher Z-scores for 
length and head 
circumference than the 
unexposed newborns at 
the end of the study
villar-García et al 
(2015)106
44 PLwH with 
controlled viral load 
,20 copies/mL
Double-blind, randomized, 
placebo-controlled trial
Oral supplementation with probiotics 
(Saccharomyces boulardii) or placebo for 
12 weeks
S. boulardii treatment 
decreased microbial 
translocation (LBP) 
and inflammation (IL-6) 
in Hiv-1-infected 
patients with long-term 
virologic suppression
Abbreviations: PLwH, people living with Hiv; ART, antiretroviral treatment; vit, vitamin; Hiv+, Hiv positive; OR, odds ratio; LBP, lipopolysaccharide-binding protein; iL-6, 
interleukin 6; ePA, eicosapentaenoic omega-3 fatty acid; DHA, decosahexaenoic omega-3 fatty acid.
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Number of articles found using key words:
HIV, nutrient supplement, and RCT (n=226)
Excluded because
did not meet
inclusion criteria
(n=184)
Probiotics without ART (n=2)
Allocated to group of RCT prior to
receiving ART that supplemented
micronutrients (n=29)
Allocated to group of RCTs of
PLWH prior to receiving ART
(n=31)
Allocated to group of RCT 
receiving ART that supplemented
micronutrients (n=9)
Allocated to group of RCTs of
PLWH receiving ART
(n=11)
Probiotics with ART (n=2)
Allocation
according to ART
RCTs with probiotics
RCTs with
micronutrients
Selection of
articles for review
Assessment of eligibility by inclusion criteria:
•  RCTs of supplementation 
•  English language 
•  Published from 2001 to present 
•  PLWH with sample size >30
participants  
Articles selected for review (n=42) 
Figure 1 Consort flow diagram.
Abbreviations: RCT, randomized clinical trial; PLwH, people living with Hiv; ART, antiretroviral treatment.
The majority of the 15 articles reported benefits such as a 
reduction in the risk of vertical transmission with multivita-
min supplementation, but not with vitamin A, in mothers with 
a low CD4 cell count, low hemoglobin and low-birth-weight 
newborns, and that multivitamin supplementation increased 
the survival of HIV-negative newborns of malnourished 
mothers with advanced HIV disease.81 Multivitamins alone 
or with vitamin A improved maternal weight gain during 
the third trimester of pregnancy.80 Multivitamins during 
pregnancy and breastfeeding reduced adverse pregnancy and 
child outcomes,72 including improving newborns’ ponderal 
weight71 and vitamin E status,83 protecting infants against 
motor developmental delays,64 reducing maternal wasting,65 
hypertension,69 symptoms of depression, improving women’s 
quality of life,63 delaying HIV disease progression during 
pregnancy,25 and improving hematological outcomes in both 
mothers and infants. Supplementation with vitamin A during 
pregnancy improved the vitamin A status of infants.70 The 
three supplementation arms, including those with vitamin A, 
decreased the burden of malaria in this cohort.61 Other reports 
from this trial, however, also described adverse effects, such 
as increased vertical transmission and increased viral load 
in breast milk with vitamin A supplementation, without 
reduction in mortality,81,83–85 and risk of developing sub-
clinical mastitis with multivitamins.84 In contrast, Kumwenda 
et al98 randomized a cohort of 697 pregnant women in Malawi 
to receive 3 mg daily of retinol or placebo, in addition to the 
standard iron and folate supplementation during pregnancy, 
and concluded that supplementation during pregnancy and 
postpartum had beneficial effects on newborns’ birth weight 
and prevention of anemia, without changing the rate of 
mother-to-child transmission.
Baum et al79 supplemented 878 PLWH in Botswana with 
a multivitamin formula (a B complex with vitamins C and 
E based on that used by Fawzi et al25) in a double-blinded 
RCT with a 2×2 factorial design. The participants were ran-
domized to selenium (200 μg of elemental selenium) alone 
in the first arm of the study, or to multivitamins alone in the 
second arm, or multivitamins and selenium in combination 
in the third arm, compared to placebo. The participants 
were followed for 24 months, and the end points were CD4 
cell count ,250 cells/μL, AIDS-defining conditions, and 
combinations of both end points as a parameter of HIV dis-
ease progression. The supplementation of multivitamin and 
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selenium was safe and reduced the risk of immune decline 
and morbidity (Table 1). These findings were consistent with 
those of Jiamton et al24 who reported that supplementation 
with a complex formula with micronutrients and cysteine 
improved the survival of persons with advanced HIV disease 
(,200 cells/μL).
Sudfeld et al,82 using the multivitamin formula previously 
described by Fawzi et al25 and Baum et al79 (B complex with 
vitamins C and E), compared the multivitamin arm with an 
experimental arm with multivitamins plus 200 μg of sele-
nium, in a cohort of 420 pregnant women enrolled at 12–27-
week gestation and followed until 6 months postpartum. 
The authors found that in primiparous women, but not in 
multiparous, the addition of selenium increased the relative 
risk of HIV-RNA shedding in breast milk.
In a cohort of 915 HIV-positive pregnant women, who 
were supplemented with multivitamins and selenium in a 
design similar to that of Sudfeld et al,82 Kupka et al58 found 
that those who were supplemented with selenium had 40% 
fewer episodes of diarrhea without increased risk of anemia. 
In another report from this trial,59 the investigators reported a 
reduced risk of mortality at 6 weeks after birth in children born 
to women supplemented with selenium and multivitamins. 
McClelland et al68 also supplemented a similar formula to 
HIV-positive women in Kenya, and they found improvement 
in immune measures in those receiving the multivitamin with 
selenium formula (CD4 cell count + 23 cells/μL, P=0.03; and 
CD8 cell counts + 74 cells/μL, P=0.005) compared to placebo; 
however, they also reported an increase in HIV genital shed-
ding among women receiving the formula.
The same formula of multivitamins with B vitamins 
and vitamin C and E25,79 was also combined with 25 mg of 
zinc, which is only slightly higher than the RDA recom-
mendation (8 mg of zinc for women and 11 mg for men) 
and compared to placebo.75 The experimental formula did 
not affect pregnancy outcomes or HIV disease progres-
sion. Villamor et al75 also reported reduction in maternal 
midarm circumference, which suggested losses in fat or 
muscle mass in pregnant women receiving zinc with the 
multivitamin formula. Mda et al99 randomized 201 children 
aged 4–24 months into a micronutrient formula appropriate 
for age or placebo for 6 months, and reported that those 
randomized into the micronutrient formula significantly 
reduced episodes of diarrhea, respiratory symptoms, and 
improved nutritional status.
Bobat et al100 randomized 96 children with HIV disease to 
receive 10 mg of elemental zinc or placebo. The children who 
received the zinc dose were less likely to get diarrhea and did 
not experience an increase in their viral load. In comparison, 
Cárcamo et al76 supplemented 159 adults with HIV with a 
high dose of zinc (100 mg of elemental zinc) during episodes 
of diarrhea and did not find an effect on the duration or 
remission of diarrhea. The comparison of these two studies 
suggest that zinc supplementation, at lower doses and as 
prevention, is more effective than during episodes of diarrhea 
at a very high dose.
In an attempt to clarify the differential effects between 
high and nutritional doses of multivitamin supplementation, 
Kawai et al57 compared a multivitamin formula that offered B 
vitamins and vitamins C and E at the Recommended Intake 
levels with the B vitamins and vitamins C and E used in 
higher doses in the aforementioned trials. No differences in 
adverse pregnancy outcomes were found between the two 
arms of the study.
In resource-limited countries, tuberculosis (TB) is a sig-
nificant cause of mortality in PLWH without ART. PLWH 
who receive isoniazid medication, either as prevention or 
treatment of TB, may need supplementation with vitamin B
6
. 
Receiving lower doses of isoniazid to prevent TB, or in high 
doses to treat it, may stir symptoms of neuropathy, because 
the medication blocks the absorption and metabolism of 
vitamin B
6
. Supplementation with vitamin B
6
 was found 
effective to prevent the symptoms of neuropathy associated 
with treatment.101 Villamor et al60 conducted an RCT of mul-
tivitamins with B
6
 and selenium compared to placebo among 
a cohort of 887 participants with pulmonary TB that included 
471 HIV/TB-coinfected people. The authors reported a reduc-
tion in peripheral neuropathy by 57% in TB patients with and 
without HIV, which is consistent with Kaiser et al23 (Table 2), 
who supplemented 40 PLWH receiving ART with a complex 
formula containing 260 mg of B
6
 and reported improvement 
in neuropathy in patients on a stable ART combination associ-
ated with this condition.
RCTs of micronutrients in PLwH 
receiving ART
Two-thirds of the studies described in Table 2, after the 
initiation of ART, used single nutrients such as zinc, sele-
nium, calcium, and vitamin D, which have been recognized 
to be deficient after initiation of ART.39,67,88,90,102 How-
ever, the articles led by Isanaka et al,87 Austin et al,86 and 
Kaiser et al23 reported the use of multiple combinations of 
multivitamins.
Isanaka et al87 compared a low dose to a high dose of 
the same formula of multivitamins supplemented to ART-
naive patients in Africa25,79 and concluded that the high dose 
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increased liver transaminases without having a significantly 
different effect on HIV disease progression. Austin et al86 
compared a complex formula with multivitamins, minerals, 
and nonnutritional antioxidants with the same complex 
formula with an added higher dose of vitamin A and 
supplemented for 13 months. This was a multisite RCT in 
PLWH in advanced disease stage, receiving an ART combi-
nation containing protease inhibitors for at least 3 months. 
All participants received multivitamins and nonnutritional 
antioxidants as shown in Table 2. The investigators reported 
a reduced rate of mortality (odds ratio =3.15, P=0.03) in 
the group that received 120,000 IU (72 mg) of β-carotene 
compared to those who only received the standard formula, 
after controlling for serum carotene and CD4 cell count at 
baseline.86
Kaiser et al23 conducted a clinical trial of PLWH on stable 
ART using a complex formula with multivitamins, minerals, 
and nonnutritional antioxidants compared to placebo for 
12 weeks. The investigators found that, compared to placebo, 
those who received the formula showed a significant increase 
in CD4 cell counts, with some reduction in neuropathy.
Two of the RCTs of supplementation addressed zinc 
deficiency in PLWH on ART. In a report from an RCT of 
zinc supplementation for 6 months, Asdamongkol et al102 
randomized into zinc or placebo supplementation a group 
of 31 PLWH with immunological discordance (achieving 
controlled viral load without increasing CD4 cell count 
.200 cells/μL) and found that CD4 cell counts significantly 
increased in patients who started the study with low plasma 
levels of zinc. These findings agreed with those of a much 
larger study by Baum et al39 of 231 adults living with HIV, 
who used illicit drugs, and were zinc deficient at randomiza-
tion. The participants received either zinc at the level of 12 mg 
of elemental zinc for women or 15 mg for men or placebo for 
18 months. Zinc supplementation prevented immune failure 
and decreased episodes of diarrhea.
As vitamin D deficiency has been identified as one of 
the side effects of long-term antiretroviral use, three of the 
reports of micronutrient supplementation after ART focused 
on vitamin D supplementation alone or with calcium.88–90 
Arpadi et al88 randomized 56 children living with HIV and 
receiving ART into 100,000 IU of vitamin D every 2 months 
and 1 g of calcium daily or placebo during 1 year; the inves-
tigators concluded that the intervention did not significantly 
affect viral control or HIV disease progression, but serum 
vitamin D significantly increased in those supplemented.
Longenecker et al89 investigated the effects of supple-
mentation with vitamin D on the endothelial function in 
PLWH. The study was an RCT that included 45 HIV patients 
on ART therapy. Participants were randomized into the 
intervention group, which received 4,000 IU vitamin D
3
, 
or into the placebo group and followed for 12 weeks. There 
was no difference in flow-mediated brachial artery dilation 
between the two groups (P=0.748). Serum vitamin D levels 
significantly increased in the intervention group (P=0.003) 
and total and non-HDL cholesterol were reduced. Interest-
ingly, vitamin D supplementation was also associated with 
increased insulin resistance. Further investigation on this 
relationship is warranted.
Kakalia et al90 also evaluated the effect of vitamin D 
supplementation on CD4 cell count in 54 children living 
with HIV, who were randomized into three groups: 800 IU 
of vitamin D/d, 1,600 IU of vitamin D/d, or no supple-
mentation. Serum vitamin D levels significantly increased 
in the 800 IU/d (P=0.0002) and 1,600 IU/d (P,0.001) 
supplementation groups compared with control. Although 
vitamin D supplementation increased serum levels, CD4 cell 
count did not increase. The investigators also concluded that 
for maintaining adequate vitamin D levels in HIV-infected 
children, intakes of ∼1,600 IU/d may be required. More 
longitudinal research is needed to identify potential risk fac-
tors for changes in bone mineral density in PLWH receiving 
specific ART combinations and develop effective medical 
and nutritional interventions.
RCTs of probiotic supplementation in 
PLwH
There have been very few trials of supplementation with pro-
biotics before initiation103,104 or concomitant with ART105,106 
in PLWH (Table 3). The majority of these trials were limited 
by small sample size, short duration of supplementation and 
one was combined with micronutrient supplementation.105 
Hummelen et al103,104 in two reports of RCTs conducted in 
ART-naive patients in Tanzania supplemented Lactobacillus 
rhamnosus GR-1. In the 2011 article, 112 participants 
received yogurt in combination with a multivitamin/mineral 
formula with omega-3 fatty acids, and the experimental 
group also received L. rhamnosus GR-1 at 109 CFU/mL. The 
investigators found that the fortified yogurt was well toler-
ated but did not significantly increase CD4 cell count. The 
main weakness of this study was that supplementation only 
occurred for 4 weeks, probably a very short time to observe 
long-term outcomes. A longer trial of supplementation of 
probiotics for 6 months by these investigators in Tanzania106 
found that supplementation with L. rhamnosus GR-1 and 
L. reuteri RC-14 did not seem to have an effect on bacterial 
vaginitis but changed the vaginal pH in a beneficial manner 
that may prevent the condition.
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Discussion
A Cochrane review that combined the results from the trials 
of vitamin A supplementation among pregnant women living 
with HIV determined that supplementation with vitamin A did 
not reduce or prevent mother-to-child HIV-1 transmission.107 
However, other investigators have confirmed benefits in other 
pregnancy outcomes such as improved birth weight, and 
lower rates of infant morbidity and mortality.72,73 A review by 
Mehta and Fawzi,55 which concurred with a 2005 Cochrane 
review,57 reported that vitamin A supplementation should be 
recommended, because it was beneficial in reducing all-cause 
mortality and morbidity in infants and children infected with 
HIV. In adults, vitamin A supplementation in excess of the 
RDA is not recommended due to its adverse effects on mother-
to-child transmission, increased HIV breast milk shedding 
and lack of effect on HIV disease progression.
The majority of studies in PLWH in Table 1, who were 
ART-naive, used formulas of multivitamins in factorial 
designs compared to single nutrients or to a combination of 
multivitamins plus the specific single nutrients or placebo. In 
contrast, most of the studies after the initiation of ART used 
single nutrients such as zinc, selenium, calcium and vitamin 
D, which have been recognized to be deficient after initia-
tion of ART.39,67,88–90,102,105,106 The report from Isanaka et al87 
suggests that supplementation with multivitamin at the RDA 
level is still safe in coadministration with ART, but high doses 
of vitamins should be avoided.
Another study assessed the effect of vitamin supplements 
on HIV shedding in breast milk in HIV-infected lactating 
women.  Tanzanian lactating women (n=594) were random-
ized into four groups: placebo, multivitamin, vitamin A and 
β-carotene, multi vitamin with vitamin A plus β-carotene. 
They found that mothers taking vitamin A and β-carotene 
had higher detectable viral load than mothers not receiving 
vitamin A. They concluded that supplementing HIV-infected 
lactating  mothers with vitamin A and β-carotene increases 
the HIV viral load in the breast milk and, therefore, increases 
the risk of mother-to-child transmission.85
The benefit of using formulas that contain multiple nutri-
ents is that vitamins and minerals work in conjunction with 
each other. Providing multiple micronutrients could influence 
several mechanisms simultaneously, and the effect, instead 
of being simply additive, becomes synergistic. One of the 
main limitations of these trials of multiple supplementation 
is that it is not possible to know which of the vitamins and 
minerals had more activity, which is important information 
to optimize formulas.
Recent studies suggest that microbial translocation 
is a source of immune activation even in PLWH with a 
suppressed HIV viral load.108,109 Elevated plasma levels of 
endotoxins, which are lipopolysaccharides derived from the 
cell walls of gram-negative bacteria and a marker of microbial 
translocation, are produced due to a defective intestinal 
barrier and dysfunctional macrophage phagocytic clearance 
of microbial products.110,111 The microbial products trigger 
monocyte/macrophage activation that induces production 
of proinflammatory cytokines and soluble CD14 (sCD14).42 
Depletion of CD4+ Th17 cells in the GI wall, early in HIV 
infection, reduces immunoprotection.112–115 The depletion 
also disrupts the microbiota of the patient, which may lead 
to greater dominance of potential pathogens, lower levels of 
lactobacillus species, and increases mucosal inflammation.116 
Modulation of gut microflora has been suggested as a safe 
and promising treatment in HIV infection.117–119
Probiotics have been shown to have favorable effects 
on alcoholic liver disease in clinical and experimental 
animal research.50–52,119 L. rhamnosus Gorbach–Goldin 
is one of the most widely studied probiotic strains with 
many well-documented benefits on several GI conditions 
and diseases.105,120 A limited number of studies using 
probiotic supplementation have been conducted in HIV 
infection;103–105,121–123 they have shown that probiotics were 
safe and effective in reducing diarrhea, nausea, and stabiliz-
ing CD4+ T-cell numbers.124 L. rhamnosus Gorbach–Goldin 
also reduced the duration and severity of diarrhea and 
improved humoral immune responses.124,125 While most of 
these studies have been limited by a small number of study 
participants and/or short treatment duration,103–106 they sup-
port the notion that probiotics may provide benefits in HIV 
infection, especially among patients with chronic alcohol 
consumption.
Summary
In summary, the majority of the reviewed RCTs on nutritional 
supplementation in PLWH were conducted before ART was 
developed or initiated, underscoring the need for trials of 
nutritional supplementation that include PLWH who are 
receiving ART, to assist in the recuperation of the immune 
response, maintaining adequate immune activation, reduce 
inflammation, and reestablishing adequate microbiota, which 
may be impaired by the long-term exposure to HIV and its 
treatment.
The composition and doses of the formulas used prior and 
after ART were diverse, but there was a convergence of the 
investigators’ judgment on using multivitamin formulas with 
a broader composition before ART was available or initiated. 
An essential objective of the nutritional supplementation 
of PLWH prior to their eligibility for ART was reversing 
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nutritional deficiencies that were identified in previous 
observational studies and delaying immune failure to prevent 
secondary infections.
After the advent and initiation of ART, the objectives of 
supplementation shifted to prevent the conditions that are 
associated with the chronic exposure to ART and associated 
with the aging of survivors, such as increased oxidative stress 
and increased morbidity for liver, kidney, cardiovascular dis-
ease, and cancers, all major causes of non-HIV-related deaths 
in PLWH.126 Our review confirms that nutritional supplemen-
tation with micronutrients and probiotics is immune stimula-
tory in both RCTs with ART-naive patients and in small trials 
with patients on ART and controlled viral load.
Conclusion
The main aim in the treatment of PLWH is preserving and 
enhancing the function of the immune system and reducing 
or controlling viral load. Immune reconstitution, however, 
does not always follow controlled viral load. While ART 
is provided according to prescribed standards to diminish 
HIV replication, the objectives of nutritional interventions 
in conjunction with ART should be achieving immune 
recovery, minimizing ART-related oxidative stress, preserv-
ing GI integrity, and preventing bacterial translocation and 
malnutrition. The literature, however, is sparse on research 
suggesting or demonstrating how to achieve these objectives 
through supplementation.
Currently, as the global effort to curtail the HIV epidemic 
is primarily directed toward broadening access to ART for 
PLWH in developing countries, and HIV is becoming a chron-
ically managed disease in developed countries, research on 
HIV and nutrition should strive to evaluate the role of nutri-
tional supplementation as a complementary therapy to ART. 
Further studies are needed to concentrate on the development 
of optimal nutrient formulas that foster immune recovery, 
decrease the short- and long-term nutritional adverse effects 
of ART, decrease bacterial translocation and immune activa-
tion, and prevent malnutrition. Trials with single nutrients 
may elucidate the role of the individual nutrients in achiev-
ing these objectives and support the incorporation of these 
nutrients into more complex formulas.
In PLWH, malnutrition inflicts an added immune-
suppressive burden on the already immune-compromised 
system. Therefore, developing interventions for the preven-
tion of nutrient deficiencies, with or without receiving ART, 
is still critical. Nutritional treatments should be individualized 
according to the patient’s stage in the disease continuum, 
the type of ART combination used, the patient’s nutritional 
status such as undernutrition and obesity, environmental 
exposure to opportunistic infections, and specific socioeco-
nomic surroundings.127 Around the world, PLWH constitute 
clusters of very diverse populations, surrounded by different 
socioeconomic conditions that affect their access to treatment 
and their nutritional status. Recommendations for nutritional 
programs for PLWH need to be designed having in consid-
eration this diversity.
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